1st Jun 2020 14:30
(Alliance News) - OptiBiotix Health PLC on Monday said its subsidiary ProBiotix Health Ltd has signed a distribution agreement with Cambridge Commodities Ltd for the distribution of LPLDL and CholBiome x3 in the UK.
CholBiome is a supplement containing LPLDL, which is OptiBiotix's probiotic strain intended to reduce cholesterol and blood pressure.
The life sciences company said the agreement gives the nutritional ingredients supplier a non-exclusive licence to distribute the products, extending the reach of LPLDL into new application areas where Cambridge Commodities has specific sector expertise such as food & beverage, sports nutrition, health & well-being and beauty.
"We are pleased to announce the signing of the distribution agreement with CCL. We believe working with CCL and similar partners around the world, provides the best opportunity to expand the range of applications for LPLDL and CholBiome x3 to a wide variety of industry sectors. This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors," said Mikkel Hvid-Hansen, commercial director of ProBiotix Health.
Shares in OptiBiotix Health were trading 2.7% lower at 57.90 pence each on Monday afternoon in London.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
OptiBiotix Health